For the first time, we revealed the clinical significance of MTA1dE4. It overexpressed in a higher percentage than total MTA1 in HBV-HCC patients and can serve as a more sensitive marker to predict the onset of early recurrence of HCC, especially in patients with low AFP. This evidence concerns the gene AFP and hepatocellular carcinoma.